[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Plaza JA, Morrison C, Magro CM: Assessment of TCR-beta clonality in a diverse group of cutaneous T-Cell infiltrates. J Cutan Pathol; 2008 Apr;35(4):358-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of TCR-beta clonality in a diverse group of cutaneous T-Cell infiltrates.
  • While some unequivocally benign infiltrates are easy to distinguish from cutaneous T-cell lymphoma (CTCL), drug-associated lymphomatoid hypersensitivity reaction and cutaneous lesions of collagen vascular disease can show cytologic atypia, clonality and an immunophenotypic profile that closely simulates CTCL and cause diagnostics difficulties.
  • Similar immunophenotypic and molecular abnormalities to those of malignant lymphoma can also be observed in pityriasis lichenoides chronica (PLC), large plaque parapsoriasis (LPP), pigmented purpuric dermatosis (PPD) and atypical lymphocytic lobular panniculitis leading one to consider these entities as forms of cutaneous lymphoid dyscrasia.
  • The purpose of our study was to evaluate the distinction of these various subcategories of cutaneous T-cell infiltrates by assessment of T-cell receptor (TCR)-beta gene rearrangement.
  • Formalin-fixed paraffin-embedded skin biopsies from 80 patients containing a T-cell dominant lymphocytic infiltrate were analyzed for TCR-beta gene rearrangement.
  • However, some cases of drug associated lymphomatoid hypersensitivity, collagen vascular disease and the various cutaneous lymphoid dyscrasias (i.e.
  • [MeSH-major] Gene Rearrangement, beta-Chain T-Cell Antigen Receptor / genetics. Genes, T-Cell Receptor / genetics. Leukemic Infiltration. Lymphoma, T-Cell, Cutaneous / genetics
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Clone Cells. Humans. Lymphocytes / pathology. Panniculitis / genetics. Panniculitis / metabolism. Panniculitis / pathology. Parapsoriasis / genetics. Parapsoriasis / metabolism. Parapsoriasis / pathology. Pigmentation Disorders. Pityriasis Lichenoides / genetics. Pityriasis Lichenoides / metabolism. Pityriasis Lichenoides / pathology. Purpura / genetics. Purpura / metabolism. Purpura / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976210.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Zheng JW, Wang YA, Zhou GY, Zhu HG, Ye WM, Zhang ZY: [Head and neck hemangiomas: how and when to treat]. Shanghai Kou Qiang Yi Xue; 2007 Aug;16(4):337-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangiomas are common benign vascular tumors of infancy characterized by a proliferative growth phase followed by very slow inevitable regression (involutive phase) between one to ten years of age, about 60% to 70% of the lesions are found in the head and neck region.
  • There are many treatment modalities reported in the literature for head and neck hemangiomas, including wait and see policy, drug therapy, sclerotherapy (steroids, bleomycin), cryotherapy, isotope radiotherapy, laser therapy, and surgical therapy.
  • A white or pink macule, a port-wine stain-like lesion initially appearing in the children can be effectively and easily removed by laser, thus preventing a growth in the size in the early stage. (2) The term of "wait and see" should be substituted by "close observation", and this approach should only be reserved for hemangiomas which are without visible growth or in the involutive phase. (3) Systematic drug therapy (steroids, interferon alpha-2a ) should be considered for large hemangioma, multiple hemangiomas, life-threatening hemangiomas and hemangiomas with complications such as ulceration, infection, bleeding, dysfunction, etc.
  • Congestive heart failure, consumptive coagulopathy, and thrombocytopenia are also urgent indications for the institution of corticoid therapy. (4) Growing hemangioma can be treated effectively by systematic drug therapy, sclerotherapy, laser therapy or combined therapy.
  • The argon laser (514 nm in wavelength, 0.5 mm in depth) is useful in the treatment of superficial telangiectasias and small, flat cutaneous hemangiomas.
  • Flashlamp-pumped pulsed-dye laser (FPDL, 585 nm or 595 nm in wavelength, 1.0-2.0 mm in depth) can be used in patients with cutaneous and flat hemangiomas at the sites of potential functional impairment.
  • For larger and deeper hemangiomas up to a depth of 2.0 cm, percutaneous interstitial Nd:YAG laser treatment may be preferred, because it may decrease possible cutaneous skin damage and more effectively reduce bulky, deep lesion. (5) Topical application of imiquimoid and intratumoral injection of steroids or bleomycin can be used in selected patients with rapidly growing hemangioma. (6) The indication for a primary operation is rare and limited to large hemangiomas in the eyelid or hemangiomas on the scalp.
  • A successful treatment of hemangiomas should be individualized and based on the size of the tumor, the localization, and the therapies available.

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17924011.001).
  • [ISSN] 1006-7248
  • [Journal-full-title] Shanghai kou qiang yi xue = Shanghai journal of stomatology
  • [ISO-abbreviation] Shanghai Kou Qiang Yi Xue
  • [Language] chi
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] China
  •  go-up   go-down


3. Karrer S, Szeimies RM, Hohenleutner U, Landthaler M: Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy. Am J Clin Dermatol; 2001;2(4):229-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy.
  • Tumor therapy is not a common indication for the use of lasers, as it is in the treatment of benign vascular skin lesions, since many alternative treatment modalities exist.
  • However, certain patients may benefit from laser therapy of premalignant and malignant skin tumors.
  • Skin tumors can be treated by laser excision, laser coagulation, laser vaporization, or photodynamic therapy (PDT).
  • In some patients, lasers and PDT might also be used effectively for the palliative treatment of cutaneous metastases.
  • [MeSH-major] Laser Therapy. Photochemotherapy. Precancerous Conditions / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Aminolevulinic Acid / therapeutic use. Bowen's Disease / drug therapy. Bowen's Disease / surgery. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Clinical Trials as Topic. Female. Follow-Up Studies. Humans. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / surgery. Laser Coagulation. Leukoplakia, Oral / drug therapy. Leukoplakia, Oral / surgery. Male. Melanoma / drug therapy. Melanoma / surgery. Middle Aged. Palliative Care. Photosensitizing Agents / therapeutic use. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / surgery. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11705250.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  • [Number-of-references] 59
  •  go-up   go-down


Advertisement
4. Kim ES, Kim KJ, Chang SE, Lee MW, Choi JH, Moon KC, Koh JK: Metaplastic ossification in a cutaneous pyogenic granuloma: a case report. J Dermatol; 2004 Apr;31(4):326-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metaplastic ossification in a cutaneous pyogenic granuloma: a case report.
  • Cutaneous ossification may occur in association with a variety of cutaneous neoplasms and inflammatory conditions, such as pilomatricomas, basal cell carcinomas, nevi, chondroid syringomas, venous stasis, and scars.
  • However, it has rarely been reported in pyogenic granuloma, a relatively common benign vascular tumor of the skin and mucous membranes.
  • We herein presented a rare case of cutaneous pyogenic granuloma with ectopic ossification on the big toe of a 37-year-old man, with high recurrence despite repeated CO2 laser ablations.
  • We propose the hypothesis that vascular endothelial growth factor (VEGF) and bone morphogenetic proteins (BMPs) play pathologic roles in the development of ectopic bone formation in pyogenic granuloma.
  • [MeSH-major] Granuloma, Pyogenic / diagnosis. Neoplasm Recurrence, Local / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Caustics / administration & dosage. Diagnosis, Differential. Drug Administration Schedule. Humans. Laser Therapy. Male. Ossification, Heterotopic / diagnosis. Ossification, Heterotopic / drug therapy. Ossification, Heterotopic / pathology. Ossification, Heterotopic / surgery. Toes. Trichloroacetic Acid / administration & dosage

  • Genetic Alliance. consumer health - Pyogenic Granuloma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TRICHLOROACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15187328.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Caustics; 5V2JDO056X / Trichloroacetic Acid
  •  go-up   go-down


5. Arbiser JL, Weiss SW, Arbiser ZK, Bravo F, Govindajaran B, Caceres-Rios H, Cotsonis G, Recavarren S, Swerlick RA, Cohen C: Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy. J Am Acad Dermatol; 2001 Feb;44(2):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy.
  • BACKGROUND: Tumors of endothelium range from benign hemangiomas of infancy to highly malignant angiosarcomas of the elderly.
  • The biologic behavior of these lesions ranges from self-resolving, in the case of hemangiomas and pyogenic granulomas, to lethal metastatic neoplasms in the case of angiosarcoma.
  • Although the clinical outcomes of these diseases are easily distinguished, the biologic basis for these differences is not well understood.
  • Activation of mitogen-activated protein kinase (MAPK) is an important signal transduction mechanism that may predict response of a tumor to chemotherapy.
  • METHODS: Skin sections from benign and malignant endothelial tumors, including hemangioma of infancy, angiosarcoma, and infectious endothelial lesions (Kaposi's sarcoma, verruga peruana) were stained with an antibody specific for phosphorylated MAPK.
  • RESULTS: We demonstrated strong expression of phosphorylated MAPK in benign endothelial tumors, including capillary hemangioma of infancy and pyogenic granuloma, and greatly decreased expression in angiosarcoma.
  • In addition, infectious endothelial tumors stained strongly with this antibody, similar to benign tumors.
  • Immunohistochemistry for phosphorylated MAPK may help the pathologist distinguish benign from malignant endothelial processes and thus guide therapy.
  • [MeSH-major] Mitogen-Activated Protein Kinases / analysis. Neoplasms, Vascular Tissue / enzymology. Skin Neoplasms / enzymology
  • [MeSH-minor] Granuloma, Pyogenic / drug therapy. Granuloma, Pyogenic / enzymology. Granuloma, Pyogenic / pathology. Hemangioendothelioma / drug therapy. Hemangioendothelioma / enzymology. Hemangioendothelioma / pathology. Hemangioma / drug therapy. Hemangioma / enzymology. Hemangioma / pathology. Hemangiosarcoma / drug therapy. Hemangiosarcoma / enzymology. Hemangiosarcoma / pathology. Humans. Immunohistochemistry. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / enzymology. Sarcoma, Kaposi / pathology. Skin Diseases / drug therapy. Skin Diseases / enzymology. Skin Diseases / pathology. Warts / drug therapy. Warts / enzymology. Warts / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11174372.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / KO8 AR02030; United States / NIAMS NIH HHS / AR / P30 AR 42687; United States / NIAMS NIH HHS / AR / R03AR44947
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down






Advertisement